Our Pipeline

Our portfolio is led by eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor that has the potential to improve upon current biologics used to treat allergic disease. We are also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, as a potential first-in-class treatment for alopecia areata.

Program Target Indication Preclinical Phase 1 Phase 2 Phase 3 Anticipated milestones in 2024
IL-13Rα1 Atopic dermatitis
Biologic naïve
  • Selection of partner to advance eblasakimab into Phase 3
  • Topline readout from dupilumab-experienced trial end 2024
Dupilumab experienced
  • Translational data in COPD to be presented 2Q 2024
DHODH Alopecia areata
  • Phase 2a interim topline data 3Q 2024


Eblasakimab is a novel, fully human, monoclonal IgG4 antibody that binds specifically to the Interleukin (IL)-13 receptor, preventing signaling of IL-4 and IL-13 through the Type 2 receptor. Eblasakimab is currently being developed as a treatment for moderate-to-severe atopic
dermatitis (AD).


Farudodstat is an orally active, potent inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), that suppresses T cell proliferation and secretion of Interferon Gamma (IFNγ) by blocking de novo production of pyrimidines required for DNA replication.

Banner Alopecia